Rimonabant's 2D structure

Rimonabant (brand name: Accomplia), a CB1 antagonist originally marketed as a treatment for obesity but was later found to possess some effects that might be beneficial in the treatment of smoking cessation. It has been withdrawn from the worldwide market (except in third world-countries like Argentina, Mexico and Russia), amidst reports that it causes suicidal ideation and depression.[1] Although the rate of suicidal ideation was so low that fewer than 1% of those treated with the drug experienced suicidal ideation. Its other side effects include nausea, vomiting, anxiety and dizziness.[2]

Properties of rimonabant
Property Value
Formula C22H21N4O
Molar mass 463.787 g/mol
InChl 1S/C22H21Cl3N4O/c1-14-20(22(30)27-28-11-3-2-4-12-28)26-29(19-10-9-17(24)13-18(19)25)21(14)15-5-7-16(23)8-6-15/h5-10,13H,2-4,11-12H2,1H3,(H,27,30)
IUPAC name 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-N-(piperidin-1-yl)-1H-pyrazole-3-carboxamide

Reference listEdit

  1. Burch, J; McKenna, C; Palmer, S; Norman, G; Glanville, J; Sculpher, M; Woolacott, N (October 2009). "Rimonabant for the treatment of overweight and obese people.". Health Technology Assessment. 13 Suppl 3: 13–22. doi:10.3310/hta13suppl3/03. PMID 19846024.
  2. Cahill, K; Stevens, S; Perera, R; Lancaster, T (May 2013). "Pharmacological interventions for smoking cessation: an overview and network meta-analysis.". The Cochrane Database of Systematic Reviews 5: CD009329. doi:10.1002/14651858.CD009329.pub2. PMID 23728690.

External linksEdit

  1. DrugBank
  3. Martindale: The Complete Drug Reference
  4. PubMed Review Search